Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is fantastic, Meach! I love it.
And you are 100% correct in that this company will not need to do a R/S. And contrary to what many might assert, Dr. Koos does care about his investors. And he does know what we have enabled him to do by way of our investments.
BMSN!
Hear, Hear!
Fantastic!
BMSN
BULL! What you see there are examples of trial and error; you fall down, you get back up and you try again. That is what SUCCESS is built on.
The WHOLE of BMSN & ENTB--that which has been assembled by and includes Koos--is what everyone needs to focus on. It is this assembly that makes this organization great. And it is this assembly that will soon present medical treatments to the world that will have a profound effect on so many lives, in so many ways.
But go on and sell your shares if you still have some. I have an urge to shop today and wouldn't mind having those if I say so myself.
BMOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOSN!
Oh, Goooooooooooood Mooooooooooooooooornin' almost everyone.
Thank you! Just the kind of post I need to start my day here!
Awesome words.
BMSN!
But wait... we have already established that there is no federal questioning and that all legal claims were a result of irreconcilable differences and disgruntled persons involved in prior business deals that did not end in their favor.
Too, we've established that the other party involved in those inflammatory accusations ain't playing with a full deck!
I wish I had your position! But, I am happy with mine, too. :)
Me, too. :)
A very good point. One that I am sure Dr. Koos has noted.
I am guessing peeps aren't quite getting the million dollar plus payment for the rights of a treatment that has PROVED itself a means to treat or even COMBAT cancer. Hmmmm, the NCI's budget for cancer research was roughly 5.1 BILLION per YEAR since 2005.
Oh yeah, an increase to the A/S to cover a million plus some change to cover the cost of owning this science, perfecting it and ultimately putting it in the hands of those with very deep pockets is a great concern.
There will be foundations out there willing to pull out a checkbook signing for ten times that before this even is marketable. Never mind what a BP or many BP's will be willing to do.
Oh, no! We will be holding hands. But, I am pretty sure, just as you are, that that plank will actually lead to a swimming pool on, wait for it..............................................................
DA MOOOOOOOOOOOOOOOOOOOOOOOOOOOOON!
:)
Inventor! I found the trail for three Hem's and a what looks like an A&B for Min. If you found more than that, stop making me suffer and email me. Also, the Market Research compilation looks like multi hits plausible for Hem.
Withholding...that is so wrong on so many levels! :p I thought I was going to go blind sifting through that data. Come on, now! Whatcha got? :)
BMSN----da mooooooooooooooon is calling! :)
What is that I can see on the horizon? It's a wee bit fuzzy, but I know it is there. Hold on...let me get a wee bit closer......
Oh my goodness! I see it now! Dang!!! That's Regen BioPharma taking the pharmaceutical world by storm with their patented treatments for blood diseases and cancer. The BP's are furiously trying to negotiate.
Oh my...and what is that ahead? Here it comes....closer...closer...
Dang!!! It's the da moooooooooooooooonmobile coming to take we longs for our ride so that we might imbibe on ceegars & alcihol in celebration.
BMSN! Just clarified their deal to secure ownership of a proven successful treatment of CANCER.
Hold on tight to them der' shares, ya'll! ;)
DO WHAT? YOU ARE JUST NOW GIVING ME A MEMBER MARK?
AIN'T THAT IT! And as hard as it has been for me to get along with you!
:p
AND FROM THE EPO (European Patent Offices)
Know what you own and buy some more if you can.
Bibliographic data: EP1898936 (A1) ? 2008-03-19
| In my patents list | EP Register | Report data error | Print
METHOD OF CANCER TREATMENT USING SIRNA SILENCING
Page bookmark EP1898936 (A1) - METHOD OF CANCER TREATMENT USING SIRNA SILENCING
Inventor(s): MIN WEIPING [CA] +
Applicant(s): LONDON HEALTH SCI CT RES INC [CA] +
Classification:
- international: A61K31/713; A61P35/00; C12N15/11; C12N15/113
- cooperative: A61K31/713; C12N15/111; C12N15/113; C12N15/1135; C12N15/1136; C12N15/1137; C12N15/1138; C12Y113/11011; C12N2310/14; C12N2320/30
Application number: EP20060761058 20060615
Priority number(s): WO2006CA00984 20060615 ; US20050690494P 20050615
Also published as: EP1898936 (A4) WO2006133561 (A1) US2009220582 (A1) US8389708 (B2) CA2612200 (A1)
Canadian Patents Database
Afficher :Third-party information liability
Patent Summary
(12) Patent Application: (11) CA 2612200
(54) English Title: METHOD OF CANCER TREATMENT USING SIRNA SILENCING
(54) French Title: METHODE DE TRAITEMENT DU CANCER PAR EXTINCTION GENIQUE AU MOYEN DE ARNSI
Abstract
Patent Details
View or Download Images
View Administrative Status
Show all claims
Representative Drawing
A single figure which represents the drawing illustrating the invention.
Top of Page
Abstracts
English Abstract
The present invention is a method for the treatment of cancer involving tumor
derived immunosuppression in a subject. The method comprises administering to
a subject one or more siRNA constructs capable of inhibiting the expression of
an immunosuppressive molecule. The invention also provides siRNA constructs
and compositions.
French Abstract
La présente invention est une méthode pour traiter un cancer impliquant une immunosuppression dérivée de tumeur chez un sujet. La méthode comprend l'administration à un sujet d'une ou plusieurs produits d'assemblage d'ARNsi capables d'inhiber l'expression d'une molécule immunosuppressive. L'invention permet aussi d'obtenir des produits d'assemblage d'ARNsi et des compositions.
Top of Page
Patent Details
(51) International Patent Classification (IPC):
A61K 31/713 (2006.01)
A61P 35/00 (2006.01)
(72) Inventors (Country):
MIN, WEI-PING (Canada)
(73) Owners (Country):
LONDON HEALTH SCIENCES CENTRE RESEARCH INC. (Canada)
(71) Applicants (Country):
LONDON HEALTH SCIENCES CENTRE RESEARCH INC. (Canada)
(74) Agent: SIM & MCBURNEY
(45) Issued:
(86) PCT Filing Date: 2006-06-15
(87) PCT Publication Date: 2006-12-21
Examination requested: 2011-06-15
(30) Availability of licence: N/A
(30) Language of filing: English
Patent Cooperation Treaty (PCT): Yes
(86) PCT Filing Number: PCT/CA2006/000984
(87) International Publication Number: WO2006/133561
(85) National Entry: 2007-12-14
Da moooooooooooon be calling for us very soon.
Research people, research. This is not business as usual. If you don't have the stomach, sell me your shares and leave it alone.
There are a couple of us that have given enough dd and a few hints to emphasize the staggering potential of what BMSN possess.
When it all hits at once and the buyers start clamoring, you will not know what hits you. You have to consider the amount of money BMSN are not only saving BP by what they are doing and HOW they are doing it, they are also setting BP up to make a LOT of money on their work. By doing that, BMSN are setting themselves up to realize a constant stream of cash flow as they place themselves soundly in this TRILLION dollar worldwide market.
On May 1, 2013 Dr. Wei Ping Min (“Min”) entered into an agreement (“Agreement”) whereby Min assigned to Regen BioPharma Inc. (“Regen”) , a wholly owned subsidiary of the Company , all right, title and interest in US Patent # 8,389,708 as well as all Patent applications from the same family corresponding to numbers PCT/CA2006/000984, CA2612200 and EP1898936.(“Min IP”)
US Patent # 8,389,708 was granted to Min with regard to his invention of a method directed to the silencing of immunosuppressive cancer causing genes using short interfering RNA (siRNA) leading to an increase in the immune response, a decrease in tumor-induced immunosuppression and a decrease in in vivo tumor progression.
As consideration for the Min IP, Regen is required to:
(a)
negotiate in good faith with Min with regards to a proposed consulting agreement whereby Min shall perform certain mutually agreed upon tasks for the benefit of Regen for consideration to Min consisting of One Hundred Thousand United States Dollars ($100,000) of the common shares of the Company valued as of the date of issuance and to be paid over a twelve month period in twelve equal installments (“Consulting Shares”) and registered under the Securities Act of 1933 on Form S-8.
(b)
Cause to be issued to Min 100,000 of the Company’s preferred shares (“Assignor Preferred Shares”) exchangeable into common shares of the Company (“Exchange Common Shares”) under the following terms and conditions:
(i)
A sufficient number of common shares shall be authorized for issuance by the Company in order that the required number of Exchange Common Shares may be issued
(ii)
Subject to (i) above, upon any date subsequent to the date of the completion of a satisfactory review by the United States Food and Drug Administration (“FDA”) of an Investigational New Drug Application (“IND”) for the Min IP submitted by Regen which shall result in the ability of Regen to lawfully begin clinical testing of the Min IP on human subjects within the United States Min shall be permitted, at his option, to exchange 33,333 of the Assignor Preferred Shares into that number of Exchange Common Shares having a value of Three Hundred Thirty Three Thousand United States Dollars ($333,000) such shares being valued at a price per share equal to the closing price as of the day written notice is given by Min to Regen of Min’s intent to exchange.
(iii)
Subject to (i) above, upon any date subsequent to the date that manufacturing procedures for the manufacture of the Min IP have been developed by Regen which comply to the Current Good Manufacturing Practices (“cGMP “) requirements of the Food Drug and Cosmetics Act of 1938 and the rules and regulations promulgated thereunder as they may apply to the manufacture of the Min IP Min shall be permitted, at Min’s option, to exchange 33,333 of the Assignor Preferred Shares into that number of Exchange Common Shares having a value of Three Hundred Thirty Three Thousand United States Dollars ($333,000) such shares being valued at a price per share equal to the closing price as of the day written notice is given by Min to Regen of Min’s intent to exchange.
(iv)
Subject to (i) above, upon any date subsequent to the date that, in connection with a lawfully administered Phase I clinical trial of the Min IP being conducted by Regen within the United States on human subjects, both of (1) a clinical trial protocol has been completed and (2) a Principal Investigator has been appointed, Min shall be permitted, at Min’s option, to exchange 33,333 of the Assignor Preferred Shares into that number of Exchange Common Shares having a value of Three Hundred Thirty Three Thousand United States Dollars ($333,000) such shares being valued at a price per share equal to the closing price as of the day written notice is given by Min to Regen of Min’s intent to exchange.
(c)
Subject to sufficient number of common shares having been authorized for issuance by the Company, Min shall receive, upon successful completion of a lawfully administered Phase I clinical trial of the Min IP being conducted by Regen within the United States on human subjects, the results of which (1) shall indicate that the Min IP can be safely tolerated by human subjects (2) shall not indicate that use of the Min IP in human subjects result in side effects of such severity that commencement of a Phase II clinical trial could not occur, and (3) establishes the optimal dosage and/or method of administration( as applicable )of the Min IP , Min shall receive that number of the common shares of BMSN which, at a price per share equal to the closing price of the shares as of the day of issuance, shall equal One Million United States Dollars ($1,000,000)
As of July 23, 2013 the Company has only 1,700,951 authorized but unissued common shares. As such, the Board has determined that the common shares authorized by the Company’s Certificate of Incorporation be increased in order that:
(a)
the Company shall be able to issue common shares to Min pursuant to the Agreement
(b)
The Company shall have a sufficient number of common shares authorized in order that it may offer common shares as consideration for the purchase and/or licensing of intellectual property.
Noted. Thank you. :)
That is not at all what the PR said.
You are disseminating untruths.
And since I have never been to da mooooooon, I think I might like BMSN to take me there! ;)
There is HemXellerate, HemaXellerate, another scion of HemXellerate and Min are presently being pursued. There might even be another that is as advanced in the process as the above mentioned.
People have no idea how much work BMSN, ENTB & MEDS have conducted in the past eighteen months. It is unbelievable how far they have gone.
It ain't over until the fat lady sings. The proposed increase is yet to be a reality.
And don't forget what the said increase will purchase: patent #4 of exclusive treatments in a trillion dollar market.
Incorrect. Pre-clinical trials have concluded with the corresponding data reflecting the required efficacy and safety for human trials complete.
Given that historical data from similar treatments exercising the same method for cell retrieval has shown to be successful and with minimal side effects in human subjects, there is no reason why the FDA will not approve the HemXellerate process for clinical trials in the very near future.
With Orphan Drug status and an increased pressure on the FDA by various cancer research groups to allow for fast tracked personalized treatment approaches, HemaXellerate is poised to go from IND application submission to completion of clinical trials in no time, comparatively speaking.
Since this treatment does not consist of a method that pumps chemicals into a patient that may or may not ultimately create toxic effects rather utilizes a process that encourages the patients own cells to fight against the disease through proliferation, this treatment very much stands out above the rest and demands the full consideration and cooperation of those charged with seeing it made available to the public.
BMSN!
Spot on, sir guru, spot on!
But, I will argue that Hem is more than a bonus--presently siRNA will not work for all cancers. So, what siRNA will not silence, stem cell therapy will. They compliment one another. Don't sell Hem too short.
:)
Well, duh! I know that dilution is the general term used for the increase of common shares.
Not always a bad thing.
Not confirmed yet that such will happen in this case, Mr. Cowboy.
Again though, not always a bad thing.
But 7.00 on the London exchange. My goodness...what is up with that?
Only 86 milly on the Aussie exchange.
Is this the same company that Westhouse Securities rated a strong buy?
Mr. Moderator, do you think you can enlighten us on BMZ? The intro page lacks material. :)
Cool indeed, Jack. Cool indeed.
I believe BP has already shown an interest and this is why BMSN was included in several market research publications for current pharma dealings.
Now, how long Koos intends to make them wait is a mystery to me.
Thanks, DK. Thanks, J!
BMSN!
Hey ya'll, LOOK! I'm not grounded anymore!!!
;)
Remember, when I spoke with Dr. Ichim on 17 July, he confirmed in the conversation that they had responded to the 2nd round of questions with the FDA and that they were very confident in what was issued to the FDA.
Obviously I did not make this up as the FACT that a 2nd round of questions with corresponding generated data was confirmed by the company in the 31 July PR.
If indeed the FDA only required data to further elaborate on efficacy, they received such prior to 17 July. This mean that they have had the data for more than two weeks. Subsequently, MORE NEWS could hit ANYTIME!
Go, Up, up & AWAY......BMSN!
Goooooooooood Mornin', ya'll! It is a fine Friday morning here near the banks of the beautiful Chesapeake Bay. I do hope most of you are feeling as grand as I am this morning and that you are steadfast in filling your heeds with useful knowledge!
And here is some to get you started:
As mentioned in the PR provided by our beloved BMSN on 31 July, the company has submitted the requested information, providing data to further show the efficacy of HemaXellerate (remember, now, safety is no longer a concern. Further testament that it works was requested). Remember now, the information has already been submitted. So what does that mean? Well, in my humble yet somewhat educated opinion, if you have a gander at the below chart, the good doctors (and that includes Dr. Koos, now!) adequately substantiated their efficacy claim. Or, translated, they have shown that the treatment is indeed very much effective!
Moreover, as I have outlined previously, unlike the vast majority of treatments under scrutiny during trials, monitoring the changes within the patient from the HemaXellerate treatment (also known as success as far as this gal is concerned) takes but a fraction of the time due to the very nature of the treatment. Please note the remarkable changes after just fourteen days.
Just look at the significant improvement in white cell count and the marrow healing (regeneration) with the HemaXellerate versus that of the placebo!
Ain't that about the pertiest thing you ever did see???
If you go digging deep enough, you are bound to find what you are looking for: this data predates 17 July. By how many days I do not know. A week maybe? A couple of days? Not sure. But certainly not more than a month.
And what exactly is PG getting at? Well, that is has been more than two weeks since the good docs at Bio-Matrix Scientific group submitted to the FDA the PROOF that HemaXellerate works!
Further, some have queried about the following, asking my opinion:
Does this really mean it could be months before an approval is provided? No! The above does not necessarily mean that. The above may very well mean that there are some FDA instructions to be carried out during the course of trials and how to correctly/sufficiently apply these instructions during trials.
They are doing everything right and all they can!
There is no talk of a R/S that I am aware of. I am pretty sure that is just hogwash.
Go, Go, Go BMSN!
There's me post for the day! :)
My thought for the day:
Safety has been proved. Efficacy has been proved by way of the information generated and submitted to the FDA. The PR clearly states the efficacy data has been generated. Again, they have generated the requested data. NOT are generating. It is DONE.
You do not file additional applications that are derived from a treatment that is denied or appears will be denied by the FDA. THAT DOESN'T HAPPEN
Every indicator--from the science/data to the above mentioned quote from yesterdays PR--clearly shows that in the very near future HemaXellerate WILL be successful in human trials and, because it will be deemed an Orphan Drug by the FDA, will soon be marketed. Following suit will be at least two more patented treatments.
All the while, the Min Science will be setting itself up to take the world of cancer treatment by storm.
GO BMSN! Go, GO, GO!
Alright, here we go:
As I have recently stated in a message to a very wise and savvy fellow investor, the best laid plans of Mice & Men...(you know the rest). Due to the very taxing day I have had, my wee summary from last nights conference is officially delayed.
HOWEVER, I am delighted to report that I have recently completed an 18 minute 57 second conversation with our beloved company, Bio-Matrix Scientific Group. I will not disclose to whom I spoke except to say that it was not Dr. Ichim (who is presently dealing with some personal matters) this time (you can read between the below listed lines to come up with your own conclusion. You'll probably be right. Unless of course you are a naysayer and conclude I spoke to no one. In which case you are very much wrong).
I want to reiterate that if the IND application for HemaXellerate had been denied, we would have known by now. BY LAW, the company is required to divulge such. Further, if you look closely at the filings coupled with taking into consideration the money that has been required to see the recent events come to fruition, you will understand that David Koos, the CEO, has had to use his own funds to see this little engine that could keep on moving.
That said, during my conversation with the company I made the sentiments of the investors very clear. Particularly at this juncture where, if for no other reason common courtesy, a PR is overdue. I also outlined for the company various attempts by some to defame the company by way of disseminating erroneous information about the company. I have no doubt that this was unknown to the company and that the company now understands very well just how vulnerable to these wretched folks they have become.
In conclusion, I was assured that a PR is forthcoming. Of course I was not told when as this would be insider trading. But I did emphasize the need for it being without much delay, if any at all and the company concurred.
In closing, I would like to challenge anyone to tell us one start up biotech company that has submitted an IND application to the FDA as quickly as this company has. Particularly one that did so without the prior financing of a BP because said company was created with BP funding. You wont find one. You can look all you want.
I have every bit of faith in this company I had when I made my first investment. If you do not yet have a clear understanding of the potential, I highly recommend you increase your dd time.
So, if you sold because you lost faith in this little engine that could by way of the negatives, I feel for you. Personally, I am buying more tomorrow.
Alright, there's my one-a-day. Goodnight.
Thanks for the Kudos, Sporty!
Like you, I feel it is staggering to think what the pps will be if (when) this company attains what the brilliant minds behind it have worked so earnestly for. All one has to do is read the vast array of documentation available to the public on not only what the company is currently working toward as a collective whole but the incredible advancements each doctor has made throughout their careers in medicine & science individually, to realize the incredible potential here.
Thanks again & I look forward to further exchanges with you as we witness the marvelous advancements of BMSN unfold.
To be clear about something, the HemXellerate product (that from which HemaXellerate is derived) is an Autologous SVF therapy. This means the cells used in this therapy are derived from a patient’s fat by way of liposuction which then undergo patented processes to finally arrive at the required state. The cells utilized in this therapy are not embryonic stem cells.
Because of the safety and ease of SVF administration—something that has already been established throughout the scientific & medical community through various types of successful procedures—it is expected that the HemXellerate therapy will be widely accepted as a successful alternative treatment to the various ailments Regen Biopharma intend to counter by way of their inventions.
Moreover, using SVF as a source of stem cells is more than forty years old; the practice of doing such has been carefully studied and documented in a plethora of publications. In fact, liposuction is performed routinely now and safety of this procedure has been previously published for rheumatoid arthritis in a 13 patient study in which patients were monitored for over one year where 80% improvement and no serious side effects were found.
So what’s the caveat? Frankly, I haven’t found one. In the world of fighting diseases, HemXellerate is very, very exciting.
That said, where is Regen with their advancements in HemaXellerate? The US Trademark is complete, the Q&A with the FDA is most likely satisfied and announcement for initiation of human trials with the likelihood Orphan Drug Status to be announced any day now. That is fact, an educated guess and a humble yet educated opinion.
They are keeping true to their timeline for the most part. Which is very, very ambitious but, too, very attainable with the great minds working behind the scenes to see all this come to fruition. And that does include David Koos. Regardless of what anyone says about him.
Given that the HemXellerate therapy has the potential to treat several if not many diseases in a trillion dollar pharmaceutical market, the monetary potential for this little company, based on their stem cell therapy alone is huge.
If I am correct with my suspicions that Orphan Drug Status for Hema is being established/finalized (however you want to put it) it will very soon be like Manna from Heaven for the company as that should be when the Whales jump in. Since, after all, it looks pretty darn good out yonder in the world of marketing when you are standing slap dab on the apex of the OD foothill.
Translated: It will start raining $$$ from those forces known as Venture Capitalists. Then it won’t be so east for this stock to be manipulated the way it is. And, those of us that have been long invested in this can finally start to see a return on our investment.
And that is before a negotiation with a BP is solidified.
Which brings me to my next point: When this stock finally does what it should be doing, there will be no need for the added dilution as outlined in the PRELIMINARY filing for the 3 billion increase for the Min technology. You know, that technology that no one else possesses, and does little thing with suppressing nasty little cancer genes. A technology invented by a doctor whose scientific appointments include but are not limited to:
Associate Professor, Department of Surgery
Associate Professor, Department of Pathology
Assocaite Professor, Department of Oncology
Immunologist, London Health Sciences Centre
Scientist, Lawson Health Research Institute
Who has received funding by such folk as Roche, the Canadian Institutes of Health, Lawson Research Institute & The Canadian Breast Cancer Fund to name a few.
No, Dr. Min might not know a little bit more about this science than the average Joe, might he?
Have I mentioned that efficacy has long since been proven in this science by the way?
In terms of what financial promise that means for Bio-Matrix Scientific group, I can’t even get my head wrapped around that figure yet. It’s a whole lot more than that nice chunk of change attached to the HemXellerate.
It infuriates me to see this company bashed as a scam. Or people question the validity of the undertakings. The composition of doctors alone is phenomenal. The advancements they have made and are currently fine tuning in the world of medicine are, well...
to da moooooooooon! ;)
There is my one post for the day.
LONG BMSN, ENTB & MEDS!
Sabai, you are very much incorrect. MEDS primary focus is ERC's to treat various diseases. ERC's differ very much from other stem cell therapies such as that which is presently being studied & tested (and FDA approved I am certain) by Regen. There are a myriad of differences among the various stem cell treatments. They might be on the same stem cell highway but they are driving completely different vehicles, carrying different cargo.
Further, the MIN science invention applies a novel method for cancer therapy--it is the silencing of immunosuppressive cancer causing genes using short interfering RNA or siRNA leading to an increase in the immune response, a decrease in tumor-induced immunosuppression and a decrease in tumor progression.
Dr. Min mentored Dr. Ichim for years. And to some great extent still very much does. If you will note, Dr. Min brings something altogether different to Regen. The collaboration of these two great minds is what is separates Regen from the rest.
I did speak in detail about the science with Dr. Ichim during my conversation with him on 17 July I believe it was. Regen does not rely on MEDS nor does MEDS rely on Regen.
I am long & strong BMSN, ENTB, & MEDS.